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67% developed neuroendocrine tumors
• Mean age of diagnosis 43 years (16 -72 years)
Mean size of tumour was 1.5cm Insulinomas (n=4)
• Mean age of diagnosis 25 years (16 -34 years)
• Glucose mean level 2.4mmol/l (range 1.7 -3.5)
• Insulin mean level 57pmol/l (range 32 -101)
• Proinsulin mean level 18pmol/l (range 15 -20)
• 100% underwent surgery, with 100% currently in remission Gastrinomas (n=16)
• Mean age of diagnosis 46 years (19 -72 years)
• Gastrin mean level 339pmol/l (range 9 -2483)
• 5 patients underwent surgery due to enlargement or worsening symptoms (2 Whipple's procedures, 2 total pancreatectomies, 1 distal pancreatectomy) • 3 patients who underwent surgery were found to have positive lymph node metastases on histology • PPIs were given to 73% of patients with gastrinomas Glucagonoma and non-functioning PNETs have been managed with surveillance only Somatostatin analogues given to 4 patients Multiple endocrine neoplasia type 1 (MEN1) is characterised by parathyroid, pituitary and pancreatic tumours in association with neoplasia of intra-thoracic endocrine tissue, adrenal glands and cutaneous manifestations. We reviewed patients in our centre attending a dedicated MEN1 clinic, where detailed radiological and biochemical surveillance is undertaken (Thakker et al. 2012 ).
27% developed pituitary adenomas
• Mean age at diagnosis 48 years (23 -60 years)
• 73% with pituitary adenomas had a lesion on MRI pituitary • 3 patients underwent curative trans-sphenoidal surgery • 5 patients were managed with dopamine agonist therapy alone
• 5 patients have been managed with surveillance only
88% developed primary hyperparathyroidism
• Mean age of diagnosis 40 years (14 -82 years)
• 55% of patients developed PHPT by 40 years
• Complication rates • 33% renal stones • 17% osteoporosis (48% had a DEXA result available)
• 71% with PHPT who had an US parathyroid had an abnormal result • 88% of those with PHPT who had a sestaMIBI had an abnormal result • 76% were treated surgically
• The characteristics of MEN1 patients presenting to our service is consistent with previous reports (Pieterman et al. 2011) .
Five patients have undergone pancreatic surgery, one of whom died 10 years after surgery. Two patients had previously unidentified lymph nodes discovered at surgery -it remains uncertain whether these patients will remain disease free. Optimal management of such patients remains unclear. NETs in MEN1 may often behave in an indolent manner and conservative management is often appropriate. Systemic therapies with conventional chemotherapy and newer biological agents are available but efficacy in this context is yet to be seen.
The wide-ranging manifestations of MEN1 emphasise the need for specialist review with a multidisciplinary team approach to achieve optimum outcomes. 
